Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism

John S. Millar, Margaret E. Brousseau, Margaret R. Diffenderfer, P. Hugh R. Barrett, Francine K. Welty, Jeffrey S. Cohn, Aisha Wilson, Megan L. Wolfe, Chorthip Nartsupha, Peter M. Schaefer,

Journal of Lipid Research · 2007 · 15 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism. Subjects, pretreated with atorvastatin (n = 9) or untreated (n = 10), received placebo followed by torcetrapib (4 weeks each). After each treatment, subjects underwent a primed-constant infusion of D3-leucine to determine the VLDL apoE production rate (PR) and fractional catabolic rate (FCR). Torcetrapib alone reduced the VLDL apoE pool size (PS) (−28%) by increasing the VLDL apoE FCR (77%) and leaving the VLDL apoE PR unchanged. In subjects pretreated with atorvastatin, torcetrapib increased the VLDL apoE FCR (25%) and PR (21%). This left the VLDL apoE PS unchanged but increased the VLDL apoE content, likely enhancing VLDL clearance and reducing LDL production in this group. Used alone, torcetrapib reduces the VLDL apoE PS by increasing the apoE FCR while leaving the VLDL apoE content unchanged. In contrast, torcetrapib added to atorvastatin treatment increases both the VLDL apoE FCR and PR, leaving the VLDL apoE PS unchanged. Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL. Cholesteryl ester transfer protein (CETP) inhibition leads to changes in lipoprotein metabolism. We studied the effect of the CETP inhibitor torcetrapib on VLDL apolipoprotein E (apoE) metabolism. Subjects, pretreated with atorvastatin (n = 9) or untreated (n = 10), received placebo followed by torcetrapib (4 weeks each). After each treatment, subjects underwent a primed-constant infusion of D3-leucine to determine the VLDL apoE production rate (PR) and fractional catabolic rate (FCR). Torcetrapib alone reduced the VLDL apoE pool size (PS) (−28%) by increasing the VLDL apoE FCR (77%) and leaving the VLDL apoE PR unchanged. In subjects pretreated with atorvastatin, torcetrapib increased the VLDL apoE FCR (25%) and PR (21%). This left the VLDL apoE PS unchanged but increased the VLDL apoE content, likely enhancing VLDL clearance and reducing LDL production in this group. Used alone, torcetrapib reduces the VLDL apoE PS by increasing the apoE FCR while leaving the VLDL apoE content unchanged. In contrast, torcetrapib added to atorvastatin treatment increases both the VLDL apoE FCR and PR, leaving the VLDL apoE PS unchanged. Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL. Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl ester from HDL to VLDL. CETP inhibitors alter lipoprotein metabolism by reducing the CETP-mediated transfer of cholesteryl ester and triglyceride between HDL and VLDL (1.Brousseau M.E. Schaefer E.J. Wolfe M.L. Bloedon L.T. Digenio A.G. Clark R.W. Mancuso J.P. Rader D.J. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in subjects with low HDL cholesterol.N. Engl. J. Med. 2004; 350: 1505-1515Crossref PubMed Scopus (712) Google Scholar). The net result of this inhibition is the accumulation of cholesteryl ester in HDL and triglyceride in VLDL, thus changing both the mass and composition of these lipoproteins (2.Brousseau M.E. Diffenderfer M.R. Millar J.S. Nartsupha C. Asztalos B.F. Welty F.K. Wolfe M.L. Rudling M. Bjorkhem I. Angelin B. et al.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1057-1064Crossref PubMed Scopus (217) Google Scholar, 3.Millar J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). The change in lipoprotein mass and composition might be expected to alter the distribution of exchangeable apolipoproteins, including apolipoprotein E (apoE), between VLDL and HDL, because the affinity of these proteins for lipoproteins is affected by lipoprotein size and composition (4.Blum C.B. Aron L. Sciacca R. Radioimmunoassay studies of human apolipoprotein E.J. Clin. Invest. 1980; 66: 1240-1250Crossref PubMed Scopus (91) Google Scholar). Redistribution of apoE among lipoproteins would be expected to influence VLDL metabolism, because apoE is a ligand for the clearance of apoB-containing lipoproteins from plasma. In addition to influencing the clearance of triglyceride-rich lipoproteins (chylomicrons and VLDL) from plasma, apoE has been hypothesized to influence the conversion of VLDL to LDL (5.Gregg R.E. Brewer Jr, H.B. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans.Clin. Chem. 1988; 34: B28-B32PubMed Google Scholar). This has been proposed to occur as a result of the preferential removal of apoE-rich VLDL and intermediate density lipoprotein (IDL) precursors of LDL. Consistent with this hypothesis, we previously reported that the apoE content of newly secreted VLDL can influence the LDL production rate (PR), with a reduced VLDL apoE content being associated with increased LDL apoB-100 production (6.Millar J.S. Lichtenstein A.H. Ordovas J.M. Dolnikowski G.G. Schaefer E.J. Human triglyceride-rich lipoprotein apoE kinetics and its relationship to LDL apo B-100 metabolism.Atherosclerosis. 2001; 155: 477-485Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar). The goal of the present study was to determine the effect of torcetrapib treatment on the metabolism of apoE. We conducted kinetic studies to define the mechanism(s) by which torcetrapib, alone or on a background with the HMG-CoA reductase inhibitor atorvastatin, influences lipoprotein metabolism (2.Brousseau M.E. Diffenderfer M.R. Millar J.S. Nartsupha C. Asztalos B.F. Welty F.K. Wolfe M.L. Rudling M. Bjorkhem I. Angelin B. et al.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1057-1064Crossref PubMed Scopus (217) Google Scholar, 3.Millar J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). The results show that CETP inhibition with torcetrapib alone significantly reduces VLDL apoE levels, primarily as a result of an enhanced clearance. Subjects treated with torcetrapib while on the background of atorvastatin treatment also showed enhanced apoE clearance, and this was counteracted by a significant increase in the PR of apoE within the VLDL fraction, resulting in no change in the VLDL apoE concentration. These changes in apoE metabolism in response to CETP inhibition with torcetrapib likely contributed to the reduction in the concentrations of apoB-containing lipoproteins observed in these subjects. Subjects were recruited at the University of Pennsylvania (Philadelphia, PA) and at Tufts-New England Medical Center (Boston, MA). Subjects met the following eligibility criteria: age between 18 and 70 years, HDL-cholesterol (HDL-C) < 40 mg/dl, triglycerides < 400 mg/dl, LDL-cholesterol (LDL-C) < 160 mg/dl, and body mass index between 18 and 35 kg/m2. Subjects having an LDL-C < 160 mg/dl while stabilized on atorvastatin 20 mg were eligible to participate in the atorvastatin arm of this study. The study protocols were approved by the Human Investigation Review Committee of each institution, and informed, written consent was obtained from each participant. The study design was a single-blind, placebo-controlled, fixed-sequence study. A total of 19 subjects were enrolled, with 9 subjects studied on a background of atorvastatin treatment. A detailed description of the study design has been reported previously (1.Brousseau M.E. Schaefer E.J. Wolfe M.L. Bloedon L.T. Digenio A.G. Clark R.W. Mancuso J.P. Rader D.J. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in subjects with low HDL cholesterol.N. Engl. J. Med. 2004; 350: 1505-1515Crossref PubMed Scopus (712) Google Scholar). Briefly, the study consisted of an introductory period of 2–4 weeks, during which time subjects were screened and, if necessary (LDL-C > 160 mg/dl), stabilized on atorvastatin 20 mg, which continued throughout the study. All subjects next received placebo for 4 weeks, followed by torcetrapib 120 mg once daily for an additional 4 weeks. Six subjects treated with torcetrapib alone also participated in a third phase, in which they received high-dose torcetrapib (120 mg twice daily) for an additional 4 weeks. At the end of each 4 week phase, subjects underwent a primed-constant infusion of deuterated leucine under constantly fed conditions to determine the kinetics of apoE (2.Brousseau M.E. Diffenderfer M.R. Millar J.S. Nartsupha C. Asztalos B.F. Welty F.K. Wolfe M.L. Rudling M. Bjorkhem I. Angelin B. et al.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1057-1064Crossref PubMed Scopus (217) Google Scholar, 3.Millar J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). At 11 AM, [5,5,5-D3]l-leucine (10 μmol/kg body weight) was injected, intravenously, as a bolus followed by a continuous infusion (10 μmol/kg body weight/h) over a 15 h period. Blood samples were collected at 0, 30, 35, and 45 min and 1, 1.5, 2, 3, 4, 6, 9, 10, 12, and 15 h after the bolus. VLDL, IDL, and LDL were isolated by sequential ultracentrifugation. ApoB levels were measured on a Hitachi 911 autoanalyzer (Hitachi, Inc.) with an immunoturbidimetric assay, using reagents and calibrators from Wako Diagnostics (Wako Chemicals USA, Richmond, VA). ApoE in plasma and lipoprotein fractions was measured by ELISA as described previously (7.Cohn J.S. Tremblay M. Amiot M. Bouthillier D. Roy M. Genest Jr., J. Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.Arterioscler. Thromb. Vasc. Biol. 1996; 16: 149-159Crossref PubMed Scopus (89) Google Scholar). The apoE/apoB molar ratio was calculated from the VLDL apoE and apoB concentrations, assuming molecular masses of 34,000 and 512,000 Da for apoE and apoB-100, respectively. ApoB-100 and apoE were isolated from VLDL by SDS-PAGE using a Tris-glycine buffer system as described previously (8.Cohn J.S. Wagner D.A. Cohn S.D. Millar J.S. Schaefer E.J. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding.J. Clin. Invest. 1990; 85: 804-811Crossref PubMed Scopus (156) Google Scholar). ApoE genotypes were determined by polymerase chain reaction as described previously (9.Tan C.E. Tai E.S. Tan C.S. Chia K.S. Lee J. Chew S.K. Ordovas J.M. APOE polymorphism and lipid profile in three ethnic groups in the Singapore population.Atherosclerosis. 2003; 170: 253-260Abstract Full Text Full Text PDF PubMed Scopus (86) Google Scholar). ApoE bands were excised from polyvinylidene difluoride membranes and in at for After removal of the the were to of using and a PubMed Scopus Google Scholar). The were for were on an were on a The of the was an of the of a rate of was throughout the The was to increase from to at increase to at and at for The was at and under conditions was to determine the under the of each for each was calculated from the under the and to a ratio to the following is the at time and the of the determined by The kinetics of VLDL apoB-100 for the subjects in this study been reported previously and for J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). the conditions of the the triglyceride < both and VLDL. the of apoE in the triglyceride-rich lipoprotein is associated with VLDL J.S. E.J. Millar J.S. Cohn S.D. R.W. Schaefer E.J. of and apoB-100 triglyceride-rich lipoproteins to increases in the plasma concentration of triglycerides and 34: Full Text PDF PubMed Google we to apoE in the triglyceride-rich lipoprotein as VLDL apoE. The kinetics of VLDL apoE were using a previously described F.K. Lichtenstein A.H. Dolnikowski G.G. Schaefer E.J. Effects of apoE on and apoB-100 kinetics with in Thromb. Vasc. Biol. PubMed Scopus Google Scholar). The was to the to the observed using a to determine the ApoE pool size in each was as PR in each was calculated using the following treated with torcetrapib alone also participated in the high-dose (120 mg torcetrapib twice daily) of the study The for this were and for this were from the kinetic as and were using the for A was to between placebo and treatment was to among treatment groups in subjects participated in the high-dose treatment was a was to determine < was The change with torcetrapib to placebo was for subjects. in plasma and apoB in subjects treated with torcetrapib 120 mg once daily been reported previously (1.Brousseau M.E. Schaefer E.J. Wolfe M.L. Bloedon L.T. Digenio A.G. Clark R.W. Mancuso J.P. Rader D.J. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in subjects with low HDL cholesterol.N. Engl. J. Med. 2004; 350: 1505-1515Crossref PubMed Scopus (712) Google Scholar, 3.Millar J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). Briefly, this consisted of and subjects the the subjects were (n = or (n = After treatment with these subjects total and triglyceride levels of and mg/dl, at the end of the placebo period. After treatment with torcetrapib 120 mg once these to and mg/dl, respectively. Plasma and VLDL apoE levels during the placebo period were and mg/dl, respectively. These to = and = mg/dl, after treatment with in plasma and VLDL apoE and apoB levels during the placebo and torcetrapib 120 mg treatment (n = (n = change placebo (n = change apolipoprotein of fed samples collected during the kinetic study. for between was determined using a in a apolipoprotein of fed samples collected during the kinetic study. for between was determined using a The subjects in the high-dose of the study (n = total and triglyceride levels of and mg/dl, at the end of the placebo period. After torcetrapib treatment (120 mg once these to 12, and mg/dl, respectively. After high-dose torcetrapib treatment (120 mg twice these to 70 and mg/dl, respectively. Plasma and VLDL apoE levels during the placebo period were and mg/dl, respectively. treatment with 120 mg torcetrapib once these to and mg/dl, and on the high they to and mg/dl, respectively. in plasma and apoB in the treated with torcetrapib 120 mg once daily while on a background of atorvastatin 20 mg been reported previously (1.Brousseau M.E. Schaefer E.J. Wolfe M.L. Bloedon L.T. Digenio A.G. Clark R.W. Mancuso J.P. Rader D.J. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in subjects with low HDL cholesterol.N. Engl. J. Med. 2004; 350: 1505-1515Crossref PubMed Scopus (712) Google Scholar, 3.Millar J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). This consisted of and of which subjects the the subjects were (n = or (n = These subjects total and triglyceride levels of 30, 4, and mg/dl, after treatment with placebo Adding torcetrapib 120 mg once daily to the atorvastatin treatment in changes in the to 10, and mg/dl, respectively. Plasma and VLDL apoE levels during the atorvastatin placebo treatment period were and mg/dl, respectively. treatment with atorvastatin torcetrapib, these to and mg/dl, of which was Subjects treated with torcetrapib 120 mg once daily a significant = in VLDL apoE pool size with the placebo treatment period This was associated with a significant increase = in the VLDL apoE These subjects also a increase in the VLDL apoE PR that was apoE and apoB-100 kinetic from subjects underwent treatment with torcetrapib 120 mg once daily (n = ApoE ApoE ApoB ApoE ApoB ApoE ApoB change fractional catabolic PR, production for between was determined using a in a fractional catabolic PR, production for between was determined using a Subjects in the high-dose of the study a reduction in the VLDL apoE pool size at the 120 mg and a reduction in the VLDL apoE pool size at the high (120 mg twice daily) of torcetrapib = with placebo treatment The in VLDL apoE pool size was associated with an increase in the VLDL apoE which increased by at the 120 mg and by at the high of torcetrapib, which was of = The VLDL apoE PR was reduced by at the 120 mg but was increased by at the high both of which were changes = apoB-100 and apoE kinetic from subjects (n = underwent (120 mg once daily) followed by high-dose (120 mg twice daily) torcetrapib ApoE ApoE ApoB ApoE ApoB-100 ApoE ApoB-100 120 mg once is significantly from placebo determined using a is significantly from placebo determined using a change placebo 120 mg twice is significantly from placebo determined using a is significantly from placebo determined using a change placebo among were determined using a This is significantly from placebo determined using a in a among were determined using a The addition of torcetrapib 120 mg once daily to atorvastatin treatment in no significant change in the VLDL apoE pool size This was associated with a significant increased the VLDL apoE FCR by = that was counteracted by a increase in the VLDL apoE PR = The net effect of these changes in VLDL apoE FCR and PR for the of change in the VLDL apoE pool apoB-100 and apoE kinetic from subjects underwent torcetrapib 120 mg treatment on a background of atorvastatin (n = ApoE ApoE ApoB ApoE ApoB ApoE ApoB change for between was determined using a in a for between was determined using a We the effect of torcetrapib treatment on the content of apoE in VLDL, IDL, and LDL by the molar ratio apoE/apoB in these VLDL the content of apoE ratio followed by ratio with LDL having the content of apoE ratio with torcetrapib 120 mg once daily no significant effect on the content of apoE in VLDL, IDL, or LDL treatment with high-dose (120 mg twice daily) torcetrapib also no significant effect on the content of apoE in VLDL, IDL, or LDL In contrast, subjects studied on a background of atorvastatin a significant increase in the content of apoE in VLDL = after torcetrapib treatment These subjects also a significant reduction in the content of apoE in in response to torcetrapib but no change in the content of apoE in LDL. CETP mediates the net of cholesteryl ester from HDL to apoB-containing lipoproteins and, in the net transfer of triglyceride from apoB-containing lipoproteins to of CETP increases by HDL cholesteryl ester with apoB-containing The of CETP and torcetrapib, in significant increases in HDL and significant in plasma triglyceride and LDL-C levels A.H. and of a cholesteryl ester transfer protein inhibitor, in a PubMed Scopus Google Scholar, R.W. et high-density lipoprotein in inhibition of cholesteryl ester transfer an study of Thromb. Vasc. Biol. 2004; PubMed Scopus Google Scholar). All of torcetrapib was after the and the and study for the study because of a significant in between subjects and atorvastatin alone of 2006; PubMed Scopus Google Scholar). Full of the of this to be studies conducted with torcetrapib the effect of CETP and CETP inhibitors on lipoprotein metabolism. In the study with torcetrapib, we that CETP inhibition significantly increased and significantly reduced plasma concentrations of VLDL, IDL, and In subjects treated with torcetrapib alone, these were associated with a in the plasma and VLDL apoE concentrations, to the that was observed for VLDL subjects added torcetrapib to atorvastatin treatment no change in plasma or VLDL apoE levels a reduction in the VLDL apoB-100 concentration. The for the in the plasma apoE concentration in subjects treated with torcetrapib alone was enhanced clearance of VLDL apoE. apoE is an exchangeable is that be from plasma of a of VLDL. results with the that increased VLDL apoE clearance was to enhanced VLDL clearance, because VLDL apoB clearance was also increased after CETP clearance of VLDL in response to torcetrapib be a result of VLDL apoE as a ligand for lipoprotein receptors (4.Blum C.B. Aron L. Sciacca R. Radioimmunoassay studies of human apolipoprotein E.J. Clin. Invest. 1980; 66: 1240-1250Crossref PubMed Scopus (91) Google Scholar). was no change in the of apoE in VLDL after torcetrapib treatment in subjects treated with torcetrapib alone, we previously reported that VLDL from these subjects is with triglyceride after torcetrapib treatment J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). This influence the of apoE in VLDL and increase the affinity of apoE for lipoprotein receptors of apolipoprotein E by in and Biol. Chem. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). triglyceride of VLDL VLDL a for lipoprotein Human lipoprotein as for lipoprotein PubMed Scopus Google or the content of exchangeable as or that influence the of VLDL leading to enhanced VLDL clearance of plasma apolipoprotein and concentrations in very low density and high density for the of the of these 1988; Full Text PDF PubMed Google Scholar, D. C. of lipoproteins with apoB by of apoE or in and 2001; Full Text Full Text PDF PubMed Google Scholar, D. Effects of on HDL and VLDL metabolism in Full Text Full Text PDF PubMed Scopus Google Scholar). In to was observed after treatment with torcetrapib alone, torcetrapib to atorvastatin treatment in no significant change in the VLDL apoE pool the VLDL apoE FCR was increased in response to torcetrapib in these likely as a result of enhanced VLDL clearance, because VLDL apoB clearance was also this was counteracted by an increase in the VLDL apoE The for the increase in the VLDL apoE PR to the reduction in concentrations in response to torcetrapib that we reported previously for these subjects (2.Brousseau M.E. Diffenderfer M.R. Millar J.S. Nartsupha C. Asztalos B.F. Welty F.K. Wolfe M.L. Rudling M. Bjorkhem I. Angelin B. et al.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1057-1064Crossref PubMed Scopus (217) Google Scholar). a of that in the in response to increased to after CETP ApoE has been reported to be in response to increased content J. Ordovas J.M. Brousseau M.E. Schaefer E.J. Effects of and on lipid content and apolipoprotein and E and LDL levels in Full Text PDF PubMed Google as a of from the has been reported to apoE production J.S. Tremblay M. R. L. C. D. Roy M. L. et of atorvastatin on plasma apoE metabolism in subjects with Full Text Full Text PDF PubMed Scopus Google in response to a in the content after inhibition of with torcetrapib the effect of atorvastatin on reducing apoE production by to LDL and HDL, leading to increased content and increased apoE We reported previously that the apoE content of VLDL, measured as the molar ratio of apoE to was a significant of the LDL apoB-100 PR, with an increased VLDL apoE content being associated with reduced LDL apoB-100 production (6.Millar J.S. Lichtenstein A.H. Ordovas J.M. Dolnikowski G.G. Schaefer E.J. Human triglyceride-rich lipoprotein apoE kinetics and its relationship to LDL apo B-100 metabolism.Atherosclerosis. 2001; 155: 477-485Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar). In the we that the VLDL apoE content was unchanged in subjects treated with torcetrapib alone but was increased significantly in subjects added torcetrapib to atorvastatin treatment. In both was significantly apoE present in and LDL, with the that VLDL is and LDL production (5.Gregg R.E. Brewer Jr, H.B. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans.Clin. Chem. 1988; 34: B28-B32PubMed Google Scholar, J. R.E. E polymorphism and 1988; PubMed Google Scholar, C. C. of apolipoprotein triglyceride-rich lipoproteins to the of LDL Full Text Full Text PDF PubMed Scopus Google Scholar). Subjects treated with torcetrapib alone no significant change in the VLDL apoE content, which the of change in the LDL apoB-100 PR in response to subjects added torcetrapib to atorvastatin treatment a significant increase in VLDL apoE content, which likely contributed the observed reduction in the LDL apoB-100 PR J.S. Wolfe M.L. Faruqi A. Brousseau M.E. Diffenderfer M.R. Nartsupha C. Welty F.K. Panagotopulos S.E. Digenio A.G. Schaefer E.J. et al.Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism.Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1350-1356Crossref PubMed Scopus (65) Google Scholar). In results the for the changes in the metabolism of apoE in response to CETP These that treatment with the CETP inhibitor torcetrapib alone the VLDL apoE pool size to a as the VLDL apoB pool size by increasing VLDL apoE clearance. The addition of torcetrapib to atorvastatin treatment no significant effect on the VLDL apoE pool an increased VLDL apoE clearance by a increase in the VLDL apoE These changes were associated with an increase in the VLDL apoE content that likely contributed to reduced LDL apoB-100 production in these subjects in response to This was in by the of and was also by the Center of the University of Pennsylvania and the Center of Tufts-New England Medical Center and were in by from the and Blood is a of the and Medical of and is by of of and The the and of each as the at each for

References

23